Head and neck sarcomas: the UCLA experience
Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the patho...
Gespeichert in:
Veröffentlicht in: | American journal of otolaryngology 2014-07, Vol.35 (4), p.476-481 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 481 |
---|---|
container_issue | 4 |
container_start_page | 476 |
container_title | American journal of otolaryngology |
container_volume | 35 |
creator | Tajudeen, Bobby A., MD Fuller, Jennifer, MD Lai, Chi, MD Grogan, Tristan, MS Elashoff, David, PhD Abemayor, Elliot, MD, PhD St. John, Maie, MD, PhD |
description | Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival. |
doi_str_mv | 10.1016/j.amjoto.2014.02.003 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230788</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196070914000386</els_id><sourcerecordid>3332017931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</originalsourceid><addsrcrecordid>eNqFUk1v1DAUtBCILoV_gFAkLkgowXb8FQ5I1QpapJU4QCVuT177hTpN4sXOVvTfk3RLC71w8uHNjN_MG0JeMloxytS7rrJDF6dYccpERXlFaf2IrJiseWmY-f6YrChrVEk1bY7Is5w7OiNELZ-SIy40Z1qIFXl7htYXdvTFiO6yyDa5ONj8vpgusDhfb04K_LXDFHB0-Jw8aW2f8cXte0zOP338tj4rN19OP69PNqVTjE9lo7Gh7dYoLxrludNohOOM6WYr69ajla7R1kjluHSttNo3xlspvWwVE1tRH5MPB93dfjugdzhOyfawS2Gw6RqiDfDvZAwX8CNegeA11cbMAm9uBVL8ucc8wRCyw763I8Z9hjkjpQyTdIG-fgDt4j6Ns70FJamSmi0biQPKpZhzwvZuGUZhuQZ0cLgGLNcAymHOeqa9-tvIHelP_PdOcY7zKmCC7G6i9iGhm8DH8L8fHgq4PozB2f4SrzHfe4E8E-Dr0oilEEwsZTCq_g2pdbBd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535065714</pqid></control><display><type>article</type><title>Head and neck sarcomas: the UCLA experience</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</creator><creatorcontrib>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</creatorcontrib><description>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</description><identifier>ISSN: 0196-0709</identifier><identifier>EISSN: 1532-818X</identifier><identifier>DOI: 10.1016/j.amjoto.2014.02.003</identifier><identifier>PMID: 24721744</identifier><identifier>CODEN: AJOTDP</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age ; Bone cancer ; California - epidemiology ; Chemotherapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Head and Neck Neoplasms - epidemiology ; Head and Neck Neoplasms - pathology ; Humans ; Incidence ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Multivariate analysis ; Neoplasm Staging ; Otolaryngology ; Radiation therapy ; Retrospective Studies ; Sarcoma - epidemiology ; Sarcoma - pathology ; Studies ; Surgery ; Survival Rate - trends ; Tumors</subject><ispartof>American journal of otolaryngology, 2014-07, Vol.35 (4), p.476-481</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited 2014</rights><rights>2014 Elsevier Inc. All rights reserved. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</citedby><cites>FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0196070914000386$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24721744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tajudeen, Bobby A., MD</creatorcontrib><creatorcontrib>Fuller, Jennifer, MD</creatorcontrib><creatorcontrib>Lai, Chi, MD</creatorcontrib><creatorcontrib>Grogan, Tristan, MS</creatorcontrib><creatorcontrib>Elashoff, David, PhD</creatorcontrib><creatorcontrib>Abemayor, Elliot, MD, PhD</creatorcontrib><creatorcontrib>St. John, Maie, MD, PhD</creatorcontrib><title>Head and neck sarcomas: the UCLA experience</title><title>American journal of otolaryngology</title><addtitle>Am J Otolaryngol</addtitle><description>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</description><subject>Age</subject><subject>Bone cancer</subject><subject>California - epidemiology</subject><subject>Chemotherapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Head and Neck Neoplasms - epidemiology</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Staging</subject><subject>Otolaryngology</subject><subject>Radiation therapy</subject><subject>Retrospective Studies</subject><subject>Sarcoma - epidemiology</subject><subject>Sarcoma - pathology</subject><subject>Studies</subject><subject>Surgery</subject><subject>Survival Rate - trends</subject><subject>Tumors</subject><issn>0196-0709</issn><issn>1532-818X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk1v1DAUtBCILoV_gFAkLkgowXb8FQ5I1QpapJU4QCVuT177hTpN4sXOVvTfk3RLC71w8uHNjN_MG0JeMloxytS7rrJDF6dYccpERXlFaf2IrJiseWmY-f6YrChrVEk1bY7Is5w7OiNELZ-SIy40Z1qIFXl7htYXdvTFiO6yyDa5ONj8vpgusDhfb04K_LXDFHB0-Jw8aW2f8cXte0zOP338tj4rN19OP69PNqVTjE9lo7Gh7dYoLxrludNohOOM6WYr69ajla7R1kjluHSttNo3xlspvWwVE1tRH5MPB93dfjugdzhOyfawS2Gw6RqiDfDvZAwX8CNegeA11cbMAm9uBVL8ucc8wRCyw763I8Z9hjkjpQyTdIG-fgDt4j6Ns70FJamSmi0biQPKpZhzwvZuGUZhuQZ0cLgGLNcAymHOeqa9-tvIHelP_PdOcY7zKmCC7G6i9iGhm8DH8L8fHgq4PozB2f4SrzHfe4E8E-Dr0oilEEwsZTCq_g2pdbBd</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Tajudeen, Bobby A., MD</creator><creator>Fuller, Jennifer, MD</creator><creator>Lai, Chi, MD</creator><creator>Grogan, Tristan, MS</creator><creator>Elashoff, David, PhD</creator><creator>Abemayor, Elliot, MD, PhD</creator><creator>St. John, Maie, MD, PhD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Head and neck sarcomas: the UCLA experience</title><author>Tajudeen, Bobby A., MD ; Fuller, Jennifer, MD ; Lai, Chi, MD ; Grogan, Tristan, MS ; Elashoff, David, PhD ; Abemayor, Elliot, MD, PhD ; St. John, Maie, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c612t-97e90fb86d496d2c7e84c21179b53fdea5c97a856c25cf5a7d98da55d5f614b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Age</topic><topic>Bone cancer</topic><topic>California - epidemiology</topic><topic>Chemotherapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Head and Neck Neoplasms - epidemiology</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Staging</topic><topic>Otolaryngology</topic><topic>Radiation therapy</topic><topic>Retrospective Studies</topic><topic>Sarcoma - epidemiology</topic><topic>Sarcoma - pathology</topic><topic>Studies</topic><topic>Surgery</topic><topic>Survival Rate - trends</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tajudeen, Bobby A., MD</creatorcontrib><creatorcontrib>Fuller, Jennifer, MD</creatorcontrib><creatorcontrib>Lai, Chi, MD</creatorcontrib><creatorcontrib>Grogan, Tristan, MS</creatorcontrib><creatorcontrib>Elashoff, David, PhD</creatorcontrib><creatorcontrib>Abemayor, Elliot, MD, PhD</creatorcontrib><creatorcontrib>St. John, Maie, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of otolaryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tajudeen, Bobby A., MD</au><au>Fuller, Jennifer, MD</au><au>Lai, Chi, MD</au><au>Grogan, Tristan, MS</au><au>Elashoff, David, PhD</au><au>Abemayor, Elliot, MD, PhD</au><au>St. John, Maie, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Head and neck sarcomas: the UCLA experience</atitle><jtitle>American journal of otolaryngology</jtitle><addtitle>Am J Otolaryngol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>35</volume><issue>4</issue><spage>476</spage><epage>481</epage><pages>476-481</pages><issn>0196-0709</issn><eissn>1532-818X</eissn><coden>AJOTDP</coden><abstract>Abstract Purpose To profile the clinical presentation, subtype distribution, and treatment results of sarcomas of the head and neck at a single tertiary academic center over an 11-year period. Materials and methods A retrospective review was performed by examining the records and reviewing the pathology of 186 patients with head and neck sarcomas treated at UCLA Medical Center from 2000 to 2011. Results The mean age of the study population was 49 ± 22 years. 58% of the patients were male and 42% were female. Median duration of follow-up for the entire group was 18.5 months. The most common presenting symptom was a mass lesion in 59.9% of patients. The nasal cavity/sinus was the most common presenting site seen in 22% of patients. Solitary fibrous tumor/hemangiopericytoma was the most common subtype. 15% of patients had evidence of prior radiation exposure. 26.3% of tumors were greater than 5 cm and 35.5% were high-grade. Margins were positive in 31.2% of patients. Lymph node metastasis was rare at 6.5%. Perineural invasion was identified in 6.5%. Among all subtypes, 5-year recurrence-free survival and overall survival were 50% and 49%, respectively. Multivariate analysis demonstrated that grade and margin status were predictors of recurrence-free survival while grade and age affected overall survival. Conclusions Head and neck sarcomas are a rare entity frequently presenting as a mass lesion. In our series, lesions tended to be high-grade with a significant portion of surgical specimens having positive margins. Grade and margin status were the most important predictors of survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24721744</pmid><doi>10.1016/j.amjoto.2014.02.003</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0196-0709 |
ispartof | American journal of otolaryngology, 2014-07, Vol.35 (4), p.476-481 |
issn | 0196-0709 1532-818X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4230788 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Age Bone cancer California - epidemiology Chemotherapy Disease-Free Survival Female Follow-Up Studies Head and Neck Neoplasms - epidemiology Head and Neck Neoplasms - pathology Humans Incidence Male Medical prognosis Metastasis Middle Aged Multivariate analysis Neoplasm Staging Otolaryngology Radiation therapy Retrospective Studies Sarcoma - epidemiology Sarcoma - pathology Studies Surgery Survival Rate - trends Tumors |
title | Head and neck sarcomas: the UCLA experience |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T13%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Head%20and%20neck%20sarcomas:%20the%20UCLA%20experience&rft.jtitle=American%20journal%20of%20otolaryngology&rft.au=Tajudeen,%20Bobby%20A.,%20MD&rft.date=2014-07-01&rft.volume=35&rft.issue=4&rft.spage=476&rft.epage=481&rft.pages=476-481&rft.issn=0196-0709&rft.eissn=1532-818X&rft.coden=AJOTDP&rft_id=info:doi/10.1016/j.amjoto.2014.02.003&rft_dat=%3Cproquest_pubme%3E3332017931%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535065714&rft_id=info:pmid/24721744&rft_els_id=S0196070914000386&rfr_iscdi=true |